trademark for preparations of butabarbital, a barbiturate.


A fast-acting sedative/hypnotic of intermediate duration of action.
Adverse effects
Drowsiness, insomnia, nightmares, headaches, dizziness, depression, excitability, restlessness, nausea, vomiting, constipation, dyspnoea.


Butabarbital, see there.
Mentioned in ?
References in periodicals archive ?
The agency requested the labeling changes for the following medications: Ambien/Ambien CR, Butisol Sodium, Carbrital, Dalmane, Doral, Halcion, Lunesta, Placidyl, Prosom, Restoril, Rozerem, Seconal and Sonata.
The label change affects drugs including Zolpidem, marketed as Ambien/Ambien CR by Sanofi-Aventis; butabarbital, marketed as Butisol Sodium by Medpointe Pharmaceuticals HLC; flurazepam, marketed as Dalmane by Valeant Pharmaceuticals; quazepam, marketed as Doral by Questcor Pharmaceuticals; triazolam, marketed as Halcion by Pharmacia & Upjohn Inc.
Amytal (amobarbial), barbs, bluebirds, blues, butisol (butabarbital), downers, goofballs, luminal (phenobarbital), 'ludes, 714s (methaqualone), seconal (secobarbital), nembutal (pentobarbital), tooties, yellow jackets
In 1988, HQ finally threw caution to the winds and published a straight-forward Drug Dosage Table listing the lethal dosages of eighteen common prescription drugs: Amytal, Butisol, Valium, Dalmane, Doriden, Noctec, Dilaudid, Miltown, Noludar, Demerol, Dolophine, Norflex, Seconal, Nembutal, Darvon, codeine, morphine, and phenobarbital.